

# BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Oili Halonen

BBS-Bioactive Bone Substitutes Plc | Company Release | September 23, 2024 at 17:00:00 EEST

## **BBS-Bioactive Bone Substitutes Oyj: Managers' Transactions - Oili Halonen**

---

Person subject to the notification requirement

Name: Oili Halonen

Position: Closely associated person

(1):Person Discharging Managerial Responsibilities In Issuer

Name: Jarmo Halonen

Position: Member of the Board

Issuer: BBS-Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 78336/6/8

---

Transaction date: 2024-09-10

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000260583

Nature of transaction: SUBSCRIPTION

Transaction details

(1): Volume: 7,178 Unit price: 0.29 EUR

Aggregated transactions (1):

Volume: 7,178 Volume weighted average price: 0.29 EUR

---

### **For more information, please contact:**

Juliusz Rakowski, CEO

+358 50 448 5132

[juliusz.rakowski@bbs-artebone.fi](mailto:juliusz.rakowski@bbs-artebone.fi)

**Certified Advisor:**

Nordic Certified Adviser AB,  
+46 70 551 67 29,  
[info@certifiedadviser.se](mailto:info@certifiedadviser.se)

**Distribution**

Nasdaq Helsinki  
<https://www.bbs-artebone.fi/>

**BBS in brief**

*BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.*

*BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.*

More information: [www.bbs-artebone.fi](http://www.bbs-artebone.fi)